Close
Patheon

News Releases

  • 29 Aug 2017
    WALTHAM, Mass., /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. Today's close follows the expiration of Thermo Fisher's initial tender offer for Patheon at $35.00 per share in cash."We're pleased to complete ourmore...
  • 22 Aug 2017
    DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The Netherlands (NYSE: PTHN) (“Patheon”), today announced that it has submitted written notice to the New York Stock Exchange (the “NYSE”) of its intention to voluntarily delist its ordinary shares, par value €0.01 per share (the “Shares”), from the NYSE. The voluntary delisting is subject to and conditioned upon (1) the initial expiration of themore...
  • 29 Jun 2017

    Investments in key service areas to meet growing customer demand

    DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical sector, today announced that it expects to invest approximately $45 million at key sites across its global network to meet growing customer demand for expanded service capabilities. “As outsourcing of Pharma development and manufacturing services continues to grow, our customers will need even moremore...

Media Contact

Mari Mansfield
4815 Emperor Blvd.,
Durham, NC 27703
(919) 226-3137
mari.mansfield@patheon.com

 
 

Media Contact

Mari Mansfield
4815 Emperor Blvd.,
Durham, NC 27703
(919) 226-3137
mari.mansfield@patheon.com